VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ISRG
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ISRGIntuitive Surgical, Inc.
$399.05$141.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ISRG
  4. Financial Ratios

Intuitive Surgical, Inc. (ISRG) Financial Ratios

Latest Ratios: P/E Ratio 47.4x · EV/EBITDA 34.4x · ROE 16.6%. (1999–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ISRG Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$141.0B$205.4B$188.9B$120.6B$96.1B$131.4B$98.4B$70.6B$56.9B$42.4B$24.9B
Enterprise Value$137.9B$202.4B$187.1B$117.8B$94.5B$130.2B$96.8B$69.6B$56.0B$38.6B$20.1B
P/E Ratio →47.4571.9681.3067.0772.7077.1092.7651.1850.5264.3733.87
P/S Ratio12.1820.4122.6216.9215.4423.0222.5815.7715.2813.579.22
P/B Ratio8.0711.4511.439.008.6410.9510.068.518.518.984.31
P/FCF39.1882.47144.92160.85100.2375.7186.0860.2457.9344.5325.20
P/OCF46.5267.7878.2466.4864.4362.9066.2844.2048.6537.1023.90

P/E links to full P/E history page with 30-year chart

ISRG EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—20.1122.4016.5415.1822.8122.2115.5315.0512.347.43
EV / EBITDA34.3855.8666.5553.0348.6361.1173.0044.0942.3833.4619.36
EV / EBIT46.8261.1169.9660.1558.8068.8992.2050.6046.7236.3121.15
EV / FCF—81.24143.48157.1898.5875.0284.6659.3157.0540.4920.31

ISRG Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin66.0%66.0%67.5%66.4%67.4%69.3%65.6%69.4%69.9%70.1%69.9%
Operating Margin29.3%29.3%28.1%24.8%25.3%31.9%24.1%30.7%32.2%33.7%35.0%
Net Profit Margin28.4%28.4%27.8%25.2%21.3%29.9%24.3%30.8%30.3%21.1%27.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE16.6%16.6%15.5%14.7%11.4%15.6%11.7%18.4%19.8%12.6%14.6%
ROA14.5%14.5%13.6%12.7%10.0%13.8%10.1%15.7%16.6%10.8%12.9%
ROIC15.0%15.0%13.9%13.1%11.6%14.4%10.2%15.8%26.8%86.8%74.2%
ROCE16.5%16.5%15.2%13.9%13.2%16.1%11.1%17.5%20.4%20.1%18.7%

ISRG Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.020.020.01——0.01—0.01———
Debt / EBITDA0.080.080.05——0.04—0.05———
Net Debt / Equity—-0.17-0.11-0.21-0.14-0.10-0.17-0.13-0.13-0.81-0.84
Net Debt / EBITDA-0.85-0.85-0.67-1.24-0.81-0.56-1.22-0.69-0.65-3.33-4.66
Debt / FCF—-1.23-1.44-3.67-1.65-0.69-1.42-0.93-0.87-4.04-4.89
Interest Coverage———————————

Net cash position: cash ($3.4B) exceeds total debt ($303M)

ISRG Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.874.874.074.764.405.086.864.535.284.557.69
Quick Ratio3.963.963.224.023.774.576.243.954.784.317.43
Cash Ratio2.962.962.303.152.903.685.363.133.733.736.82
Asset Turnover—0.490.440.460.480.420.390.460.470.540.42
Inventory Turnover1.861.861.831.962.272.982.492.302.743.884.47
Days Sales Outstanding—59.0559.2964.9462.9657.0860.8557.7366.8759.2558.06

ISRG Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield2.1%1.4%1.2%1.5%1.4%1.3%1.1%2.0%2.0%1.6%3.0%
FCF Yield2.6%1.2%0.7%0.6%1.0%1.3%1.2%1.7%1.7%2.2%4.0%
Buyback Yield1.6%1.1%0.0%0.3%2.7%0.0%0.1%0.4%0.0%5.4%0.2%
Total Shareholder Yield1.6%1.1%0.0%0.3%2.7%0.0%0.1%0.4%0.0%5.4%0.2%
Shares Outstanding—$363M$362M$357M$362M$366M$361M$359M$356M$349M$354M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Premium Multiple On Compressing Margins

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiple Outruns Margin Run-Rate

At 57.5x trailing earnings and 43.3x EV/EBITDA, ISRG trades at roughly double Stryker's 36.6x P/E and twice its 21.4x EV/EBITDA, per compiled peer data, a premium that appears to price sustained mid-20s revenue growth rather than current margin trajectory.

The 40.4x forward P/E versus 57.5x trailing implies the market is underwriting meaningful earnings recovery from 2026Q3's depressed 17.1% net margin back toward the 28-30% range that prevailed through 2025-2026, so the valuation is sensitive to whether the SG&A spike proves transitory. PEG of 2.64 sits above Stryker's 2.46 and Medtronic's 3.66, suggesting ISRG is neither the pure growth play nor the value option in the group. Notably, P/FCF of 64.15x exceeds the P/E, which may indicate that reported free cash flow — despite a 36.4% FCF margin — is flattered by working capital inflows and depressed earnings in the latest quarter, warranting scrutiny of the multiple's denominator.

Gross Strength Offset by Cost Spike

Gross margin reached 68.4% in 2026Q3 yet operating margin fell to 19.4% from 33.6% a quarter earlier, according to reported quarterly ratios, a 1,420 basis point swing that appears driven by the SG&A surge rather than underlying pricing deterioration.

The gross margin trajectory — up roughly 370 basis points from the 64.7% trough in 2025Q1 — suggests product mix and pricing remain structurally favorable, leaving operating margin, not gross margin, as the swing factor for normalized earning power. Stripping the 2026Q3 anomaly, operating margins of 30-33% across five of the last six quarters compare favorably against peer net margins clustered at 12.9-14.4%, indicating ISRG's underlying earning power still leads the group if the cost line normalizes. However, if the elevated SG&A level persists, the 19.4% print would become the relevant base, compressing the profitability gap versus Stryker and Boston Scientific materially.

Returns Lag Peers Despite Zero Leverage

Quarterly ROIC slipped to 3.1% in 2026Q3 from 4.7% in 2026Q2, based on ISRG's reported ratio data, while quarterly ROE of 3.0% annualizes near 12%, below Stryker's 16.4% and Medtronic's 10.5% trailing returns on equity.

Because ISRG carries virtually no debt, its ROE and ROIC converge closely — 3.0% versus 3.1% in the latest quarter — meaning the shortfall versus peers is a function of margin and asset-base size rather than capital structure, which peers leverage at 0.51-0.73x D/E to boost ROE. The recent ROIC decline from the 4.7% level appears consistent with the asset base expanding (total assets up ~16% over ten quarters, PPE up 39%) faster than the earnings depressed by the Q3 cost spike. Investors should note that a goodwill step-up to $613M and rising PPE enlarge the invested-capital denominator, so a return to 4.5%+ quarterly ROIC would require earnings growth to outpace an increasingly asset-heavy balance sheet.

Inventory Hoarding Drives Extended Cycle

ISRG's cash conversion cycle stretched to 223 days in 2026Q3, with 198 days tied up in inventory, as shown in reported working capital ratios, reflecting the razor-razorblade model where instrument and accessory stock supports a growing installed base.

With DSO steady at 48-57 days and DPO at 25-30 days, virtually all of the cycle length sits in inventory, which has climbed from 172 days in 2025Q1 to 198 days in 2026Q3 — a trend that may indicate precautionary stock building ahead of new system placements or supply-chain buffering rather than demand weakness. Asset turnover of 0.15 remains the structural constraint on returns: each dollar of assets generates only 15 cents of quarterly revenue, so ROIC improvement depends far more on margin recovery than on turning assets faster. Against peers, none of whom disclose comparable sub-scale turnover in this dataset, the comparison is limited, but the directional drift toward a longer cycle is worth monitoring for any sign of channel inventory accumulation.

Unlevered Balance Sheet Absorbs Buyback Drag

With essentially no debt outstanding and the current ratio at 3.33 in 2026Q3, down from 6.03 in 2026Q1, based on recent SEC filings, ISRG's liquidity buffer has compressed roughly 45% yet still exceeds Stryker's 1.89x.

Debt-to-equity is effectively nil in eight of ten quarters with a transient $302.8M balance in 2025Q4, and interest coverage is not calculable given the absence of meaningful interest expense — a posture that leaves ISRG structurally insulated from refinancing risk while peers carry 0.5-0.73x leverage. The compression in the current ratio from 6.03 to 3.33 alongside retained earnings falling $2.3B sequentially appears linked to the $3.0B buyback in 2026Q3, which suggests the liquidity trend is a capital-allocation choice rather than operating deterioration. That said, the quick ratio of 2.49 remains well above 1.0, and even under a scenario where inventory realization slows materially, the absence of debt service obligations means covenant or solvency risk appears remote on reported figures.

Trailing P/E Misreads True Economics

The trailing P/E of 57.47 is the ratio most likely misapplied to ISRG, since stock compensation equal to 41% of net income and a one-quarter SG&A spike distort earnings, arguing for an EV-based or SBC-adjusted multiple instead.

Because ISRG repurchases shares aggressively rather than paying dividends, buybacks mechanically shrink the share count and inflate forward EPS, which flatters both the 40.4x forward P/E and the 2.64 PEG without any corresponding improvement in operating economics — the market is effectively being shown a growth rate partly manufactured by capital return. The preferred adjustments would be an EV/EBITDA multiple excluding the recurring portion of stock compensation — cumulative SBC of roughly $1.98B over ten quarters is a genuine economic cost — or EV/Sales anchored to installed-base instrument revenue growth, both of which strip the earnings denominator of the distortions. On that adjusted lens, the 43.26x EV/EBITDA versus Stryker's 21.39x is the cleaner read of the premium investors are actually paying, and it makes normalization of the 2026Q3 cost line the single most consequential variable in the thesis.

Download Financial Ratios Data

Includes 30+ ratios · 27 years · Updated daily

Consensus & Technical Research Suite
Open ISRG Terminal

ISRG Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ISRG — Frequently Asked Questions

Quick answers to the most common questions about buying ISRG stock.

What is Intuitive Surgical, Inc.'s P/E ratio?

Intuitive Surgical, Inc.'s current P/E ratio is 47.4x. The historical average is 53.8x. This places it at the 36th percentile of its historical range.

What is Intuitive Surgical, Inc.'s EV/EBITDA?

Intuitive Surgical, Inc.'s current EV/EBITDA is 34.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 38.7x.

What is Intuitive Surgical, Inc.'s ROE?

Intuitive Surgical, Inc.'s return on equity (ROE) is 16.6%. The historical average is 7.2%.

Is ISRG stock overvalued?

Based on historical data, Intuitive Surgical, Inc. is trading at a P/E of 47.4x. This is at the 36th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Intuitive Surgical, Inc.'s profit margins?

Intuitive Surgical, Inc. has 66.0% gross margin and 29.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Intuitive Surgical, Inc. have?

Intuitive Surgical, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.